Most researchers looking for CJC-1295 in Lubná quickly find that local retail options are essentially nonexistent. What this means for Lubná researchers is that physical proximity is irrelevant compared to your ability to assess COA data — and those evaluation tools are available to every researcher. Separating properly characterised CJC-1295 from the rest of the market requires three things: an HPLC chromatogram showing ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. This guide guides Lubná researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
How CJC-1295 Works — Mechanisms & Research
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Lubná studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Evaluate CJC-1295 Vendors
Before looking at individual vendors, establish a quality benchmark — so you can tell whether a COA is complete and credible. Mass spectrometry in the COA verifies that the main HPLC peak is actually CJC-1295 and not another compound with similar chromatographic behaviour — HPLC purity alone provides no identity confirmation. For Lubná researchers evaluating new suppliers: a modest first purchase to test the product before placing larger orders is what experienced peptide researchers consistently do. For Lubná researchers making a first CJC-1295 purchase: verify the vendor against this framework, start with a modest quantity, and verify batch traceability on arrival before use.
Order CJC-1295 — ships to Lubná
COA-verified · International tracking · Research grade
CJC-1295 is sold for research purposes only and is not approved for human use by the FDA or equivalent agencies worldwide — all information here is educational. Storage requirements for CJC-1295: lyophilised powder at freezer temperature, reconstituted solution refrigerated at 2-8°C and consumed within 4 weeks; reconstitute only with bacteriostatic water. Verify the endotoxin level in your CJC-1295 batch COA before any protocol involving administration — look for results expressed as EU/mg or EU/mL and compare against acceptable research limits for your application. For any individual considering CJC-1295 outside a formal research context: speak with a healthcare professional — this compound is not approved for human use and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
